Bone marrow derived stem cell therapy for type 2 diabetes mellitus
Abstract:
In this study, 6 patients with type 2 diabetes (T2D) underwent autologous bone marrow
mononuclear stem cell (BM-MNSC) infusion into the celiac and superior mesenteric arteries without
pretreatment with any myeloablative or immune-suppressive therapy. Five of 6 (83%) showed normalization
of their fasting glucose and the glycosylated hemoglobin (HbA1C) with significant reduction of their
medication requirements. The HbA1C dropped on average 2.2 points. The three patients with diabetic
complications showed improvement or stabilization and most patients reported improved energy and
stamina. The durations of response varied between 6 months and 2 years. No patients had any significant
adverse effects.
Full Text:
Go Back
